Related Experiment Videos
Leukotrienes and their antagonists in allergic disorders
J M Negro1, J C Miralles, J L Ortiz
1Allergology Section, H.U. Virgen de la Arrixaca, El Palmar, Murcia, Spain.
Allergologia Et Immunopathologia
|March 1, 1997
Summary
Cysteinyl leukotriene antagonists show promise for treating asthma and allergic rhinitis by inhibiting bronchoconstriction and airway inflammation. These compounds improve symptoms and lung function in patients, offering a potential therapeutic breakthrough.
Area of Science:
- Pharmacology
- Immunology
- Respiratory Medicine
Background:
- Cysteinyl leukotrienes are key mediators in asthma and allergic rhinitis.
- Inhibiting their action presents a potential therapeutic strategy for these conditions.
Purpose of the Study:
- To review leukotriene antagonists and their efficacy in asthma and allergic rhinitis.
- To examine the mechanisms and effects of specific cysteinyl leukotriene receptor antagonists and 5-lipoxygenase inhibitors.
Main Methods:
- Review of clinical studies involving leukotriene receptor antagonists (e.g., LY-171883, ICI-204219).
- Evaluation of NZ-107's effects on airway inflammation induced by LTB4, IL-5, and PAF.
- Assessment of U-75302's impact on eosinophil chemotaxis and lung eosinophilia.
Main Results:
- Leukotriene antagonists inhibited bronchoconstriction in asthmatic patients.
- Compounds demonstrated improved symptoms, FEV1, and reduced beta 2-agonist use.
- NZ-107 suppressed eosinophilia and neutrophilia but not neutrophil activation.
- U-75302 inhibited eosinophil chemotaxis and lung eosinophilia in vivo.
Conclusions:
- Cysteinyl leukotriene antagonists offer beneficial effects in asthma and allergic rhinitis.
- Further research is required to fully elucidate the mechanisms of action for these compounds.